Bleeding Disorders Treatment Market Report-Forecast till 2027

Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, and Others), Drug Class (Plasma-Derived Coagulation Factor Concentrates Market and Others), Treatment (Desmopressin, Hormone Replacement Therapy), and Region-Global Forecast till 2027

ID: MRFR/Pharma/5129-HCR | February 2021 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


The Global Bleeding Disorders Treatment Market is expected to register a growth of significant CAGR 10.0% during the forecast period (2018–2023).


A bleeding disorder is a condition where there is a problem with the body’s clotting method. This disorder leads to heavy and protracted bleeding after an injury. The bleeding process can also start on its own. Most of the types of bleeding disorders are hereditary but some are acquired due to liver diseases, side effects of certain medications, low red blood cell count, vitamin K deficiency and others. The global bleeding disorders treatment market is expected to witness fast growth during the forecast period due to growth in the number of people suffering from liver diseases, anemia, and other blood coagulation disorders.


The global bleeding disorders treatment market is seeing a rise due to growth in the number of diagnosed patients with bleeding disorders, rising research and development activities and investments by key players growth in awareness about bleeding disorders especially hemophilia and positive government initiatives in the developed countries towards establishing a wide network of diagnosis and treatment centers complementing the market growth. However, the absence of access to proper treatment due to the high cost of medication and the shortage of skilled health professionals hinders the growth of the market.


Segmentation


The global bleeding disorders treatment market has been segmented on the basis of type, drug class, treatment and end users.


On the basis of type, the market has been classified as hemophilia A, hemophilia B, Von Willebrand Disease (vWD) and others.


On the basis of drug class, the market has been classified as plasma-derived coagulation factor concentrates market, global recombinant coagulation factor concentrate market, global others bleeding disorders treatment market.


On the basis of treatment, the market has been classified as desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic/clot-stabilizing drugs, fibrin sealants, drugs applied to cuts and pipeline analysis (phase I, phase II and phase III clinical trials)


On the basis of end users, the market has been classified as hospitals, clinics, specialty clinics, research institutes, and others.


On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.


The European bleeding disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The bleeding disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bleeding disorders treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Bleeding Disorders Treatment Market Share, by Region, 2017 (%)


Global Bleeding Disorders Treatment Market Share, by Region, 2017 (%)


Source: MRFR Analysis


In the bleeding disorders treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into drugs. According to the Hemophilia Federation of America, around 20,000 people are affected by hemophilia and approximately 1% of the population is suffering from Von Willebrand Disease (VWD).


The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to Statista, around 149,764 people were diagnosed with hemophilia A and about 10,811 people were diagnosed with other platelet disorders in the year 2016.


Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. According to the annual report survey of 2015 by the World Federation of Hemophilia, it is estimated that there were 17,346 million people suffering from hemophilia.


The market in the Middle East & Africa is expected to account for the smallest share of the global bleeding disorders treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global bleeding disorders treatment market are Shire Plc, Bayer Pharmaceuticals, Novo Nordisk A/S, Pfizer Inc., Biogen Idec, CSL Behring, Grifols, Octapharma, Sun Pharmaceutical Industries Ltd., BDI Pharma, Ferring Pharmaceuticals, and others.


Global Bleeding Disorders Treatment Market, by Type



  • Hemophilia A

  • Hemophilia B

  • Von Willebrand Disease (vWD)

  • Others


Global Bleeding Disorders Treatment Market, by Drug Class



  • Plasma-derived coagulation factor concentrates market

  • Global recombinant coagulation factor concentrate market

  • Global others bleeding disorders treatment market


Global Bleeding Disorders Treatment Market, by Treatment



  • Medication

  • Desmopressin (DDAVP)

  • Hormone replacement therapy

  • Contraceptives

  • Anti-fibrinolytic/clot-stabilizing drugs

  • Fibrin sealants

  • Drugs applied to cuts

  • Pipeline analysis (phase I, phase II and phase III clinical trials)


Global Bleeding Disorders Treatment Market, by End-Users



  • Hospitals

  • Clinics

  • Research Institutes

  • Others


Global Bleeding Disorders Treatment Market, by Region



  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Middle East

  • Africa


Company Profiles



  • Shire Plc

  • Bayer Pharmaceuticals

  • Novo Nordisk A/S

  • Pfizer Inc.

  • Biogen Inc.

  • CSL Behring

  • Grifols

  • Octapharma

  • Sun Pharmaceutical Industries Ltd.

  • BDI Pharma

  • Ferring Pharmaceuticals

  • Others


Intended Audience



  • Manufacturers and distributors

  • Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)

  • Research institutes

  • Contract manufacturing organizations (CMOs)

  • Government associations

  • Market research and consulting firms

  • Venture capitalists and investors



Frequently Asked Questions (FAQ) :


The bleeding disorders treatment market is projected to grow at a 10.0% CAGR between 2020-2027.

North America is projected to command the largest share in the bleeding disorders treatment market.

End users of bleeding disorders treatment market include specialty clinics, hospitals, clinics, and others.

Favorable compensation policies and increasing awareness may limit market growth.

High medication costs may limit market growth.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Bleeding disorders Treatment Market, by Type

6.1 Introduction

6.2 Hemophilia A

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Hemophilia B

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.4 Von Willebrand Disease (vWD)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Bleeding disorders Treatment Market, by Drug Class

7.1 Introduction

7.2 Plasma-Derived Coagulation Factor Concentrates Market

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Global Recombinant Coagulation Factor Concentrate Market

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Global Others Bleeding Disorders Treatment Market

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Bleeding disorders Treatment Market, by Treatment

8.1 Introduction

8.2 Desmopressin (DDAVP)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Hormone Replacement Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Contraceptives

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.5 Anti-Fibrinolytic/Clot-Stabilizing Drugs

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Fibrin Sealants

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Drugs applied to cuts

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.6 Pipeline Analysis (Phase I, Phase II and Phase III Clinical Trials)

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Bleeding disorders Treatment Market, by End-Users

9.1 Introduction

9.2 Hospitals

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.3 Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.4 Research Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

9.5 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 10. Global Bleeding disorders Treatment Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Shire Plc

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Bayer Pharmaceuticals

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

10.2.5 SWOT Analysis

12.3 Novo Nordisk A/S

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Pfizer Inc.

12.4.1 Company Overview

12.4.2 Technology/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Biogen Idec

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 CSL Behring

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Grifols

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Octapharma

12.8.1 Overview

12.8.2 Type/ Technology Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Sun Pharmaceutical Industries Ltd.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 BDI Pharma

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Ferring Pharmaceuticals

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Others

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

Chapter 13. MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Bleeding Disorders Treatment Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Bleeding disorders Treatment Synopsis, 2020–2027

Table 2 Global Bleeding disorders TreatmentEstimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Bleeding disorders Treatment Market by Region, 2020–2027 (USD Million)

Table 4 Global Bleeding disorders Treatment Market by Type, 2020–2027 (USD Million)

Table 5 Global Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 6 Global Bleeding disorders Treatment Market by Treatment, 2020–2027 (USD Million)

Table 7 Global Bleeding disorders Treatment MarketEnd-users, 2020–2027 (USD Million)

Table 8 North America: Bleeding disorders Treatment Market by Type, 2020–2027 (USD

Million)

Table 9 North America: Bleeding disorders Treatment Market by Drug Class, 2020–2027 (USD Million)

Table 10 North America: Bleeding disorders Treatment Market by Treatment, 2020–2027 (USD Million)

Table 11 North America: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 12 US: Bleeding disorders Treatment Market by Type, 2020–2027 (USD Million)

Table 13 US: Bleeding disorders TreatmentMarketby Drug Class, 2020–2027 (USD Million)

Table 14 US: Bleeding disorders TreatmentMarketby Treatment, 2020–2027 (USD Million)

Table 15 US: Bleeding disorders Treatment Market by End-users, 2020–2027 (USD Million)

Table 16 Canada: Bleeding disorders Treatment Market by Type, 2020–2027 (USD Million)

Table 17 Canada: Bleeding disorders Treatment Market by Drug Class, 2020–2027 (USD Million)

Table 18 Canada: Bleeding disorders Treatment Market by Treatment, 2020–2027 (USD Million)

Table 19 Canada: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 20 South America: Bleeding disorders Treatment Market by Type, 2020–2027 (USD Million)

Table 21 South America: Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 22 South America: Bleeding disorders Treatment by Treatment, 2020–2027 (USD Million)

Table 23 South America: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 24 Europe: Bleeding disorders Treatment by Type, 2020–2027 (USD Million)

Table 25 Europe: Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 26 Europe: Bleeding disorders Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 27 Europe: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 28 Western Europe: Bleeding disorders Treatment by Type, 2020–2027 (USD Million)

Table 29 Western Europe: Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 30 Western Europe: Bleeding disorders Treatment by Treatment, 2020–2027 (USD Million)

Table 31 Western Europe: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 32 Eastern Europe: Bleeding disorders Treatment by Type, 2020–2027 (USD Million)

Table 33 Eastern Europe Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 34 Eastern Europe Bleeding disorders Treatment by Treatment, 2020–2027 (USD Million)

Table 35 Eastern Europe: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 36 Asia-Pacific: Bleeding disorders Treatment by Type, 2020–2027 (USD Million)

Table 37 Asia-Pacific: Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 38 Asia-Pacific: Bleeding disorders Treatment by Treatment, 2020–2027 (USD Million)

Table 39 Asia-Pacific: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

Table 40 Middle East & Africa: Bleeding disorders Treatment by Type, 2020–2027 (USD Million)

Table 41 Middle East & Africa Bleeding disorders Treatment by Drug Class, 2020–2027 (USD Million)

Table 42 Middle East & Africa: Bleeding disorders Treatment Market, by Treatment, 2020–2027 (USD Million)

Table 43 Middle East & Africa: Bleeding disorders Treatment by End-users, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Bleeding disorders Treatment

Figure 3 Segmentation Market Dynamics for Global Bleeding disorders Treatment

Figure 4 Global Bleeding disorders Treatment Industry Market Share, by Type, 2020

Figure 5 Global Bleeding disorders Treatmentby End-users, 2020–2027 (USD Million)

Figure 6 Global Bleeding disorders Treatment MarketShare, by Region, 2020

Figure 7 North America: Bleeding disorders Treatment Market Share, by Country, 2020

Figure 8 Europe: Bleeding disorders Treatment Market Share, by Country, 2020

Figure 9 Asia-Pacific: Bleeding disorders TreatmentMarket Share, by Country, 2020

Figure 10Middle East & Africa: Bleeding disorders TreatmentMarket Share, by Country, 2020

Figure 11Global Bleeding disorders Treatment: Company Market Share Analysis, 2020 (%)

Figure 12Shire Plc.: Key Financials

Figure 13Shire Plc: Segmental Revenue

Figure 14 Shire Plc: Geographical Revenue

Figure 15Bayer Pharmaceuticals: Key Financials

Figure 16Bayer Pharmaceuticals: Segmental Revenue

Figure 17Bayer Pharmaceuticals: Geographical Revenue

Figure 18Novo Nordisk A/S: Key Financials

Figure 19Novo Nordisk A/S: Segmental Revenue

Figure 20Novo Nordisk A/S: Geographical Revenue

Figure 21Pfizer Inc.: Key Financials

Figure 22Pfizer Inc.: Segmental Revenue

Figure 23Pfizer Inc.: Geographical Revenue

Figure 24Biogen Idec: Key Financials

Figure 25Biogen Idec: Segmental Revenue

Figure 26Biogen Idec: Geographical Revenue

Figure 27CSL Behring: Key Financials

Figure 28 CSL Behring: Segmental Revenue

Figure 29 CSL Behring: Geographical Revenue

Figure 30Grifols: Key Financials

Figure 31Grifols: Segmental Revenue

Figure 32Grifols: Geographical Revenue

Figure 33Octapharma: Key Financials

Figure 34Octapharma: Segmental Revenue

Figure 35Octapharma: Geographical Revenue

Figure 36Sun Pharmaceutical Industries Ltd.: Key Financials

Figure 37 Sun Pharmaceutical Industries Ltd.: Segmental Revenue

Figure 38Sun Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 39BDI Pharma: Key Financials

Figure 40BDI Pharma: Segmental Revenue

Figure 41BDI Pharma: Geographical Revenue

Figure 42Ferring Pharmaceuticals: Key Financials

Figure 43 Ferring Pharmaceuticals: Segmental Revenue

Figure 44 Ferring Pharmaceuticals: Geographical Revenue

Figure 45 Others: Key Financials

Figure 46 Others: Segmental Revenue

Figure 47 Others: Geographical Revenue